Synthesis, Characterization, and Biological Evaluation of New Derivatives Targeting MbtI as Antitubercular Agents
Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most dangerous infectious diseases worldwide. Because several pathogenic strains of <i>Mycobacterium tuberculosis</i> (Mtb) have developed resistance against most of the established anti-TB drugs, new therapeut...
Saved in:
Main Authors: | Matteo Mori (Author), Giovanni Stelitano (Author), Laurent R. Chiarelli (Author), Giulia Cazzaniga (Author), Arianna Gelain (Author), Daniela Barlocco (Author), Elena Pini (Author), Fiorella Meneghetti (Author), Stefania Villa (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents
by: Laurent R. Chiarelli, et al.
Published: (2019) -
Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery
by: Matteo Mori, et al.
Published: (2023) -
Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections
by: Matteo Mori, et al.
Published: (2022) -
Targeting Siderophore-Mediated Iron Uptake in <i>M. abscessus</i>: A New Strategy to Limit the Virulence of Non-Tuberculous Mycobacteria
by: Matteo Mori, et al.
Published: (2023) -
Novel Antibacterial Agents 2022
by: Fiorella Meneghetti, et al.
Published: (2024)